Physician profile
Mark J Bergman
NPI 1063512002
$13,371.54
in general payments reported to CMS, 2019-2025
52 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,086 · 2020: $1,276 · 2021: $2,345 · 2022: $2,345 · 2023: $1,888 · 2024: $1,855 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,318.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,264.38 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,253.12 | 2019-2025 | |
| Novo Nordisk INC | $957.44 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $784.87 | 2020-2024 | Cardiomems |
| Merck Sharp & Dohme LLC | $778.87 | 2019-2025 | Verquvo, Gardasil 9, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $750.43 | 2019-2025 | Jardiance |
| Pfizer INC. | $708.22 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $668.66 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $500.72 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $442.18 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $373.98 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $370.83 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $298.70 | 2019-2025 | Farxiga, Wainua, Breztri |
| Astellas Pharma US INC | $296.35 | 2019-2023 | Veozah, Lexiscan |
| E.R. Squibb & Sons, L.L.C. | $293.41 | 2019-2025 | Camzyos, Eliquis |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $238.30 | 2022-2025 | |
| Eisai INC. | $230.63 | 2020-2021 | |
| Abbvie INC. | $219.37 | 2019-2025 | |
| Azurity Pharmaceuticals, INC. | $215.28 | 2023-2025 | Edarbi, Edarbyclor, Horizant |
| Kowa Pharmaceuticals America, INC. | $211.96 | 2019-2023 | Seglentis, Livalo |
| Arbor Pharmaceuticals, INC. | $191.46 | 2019-2022 | |
| Edwards Lifesciences Corporation | $181.85 | 2022 | |
| Boston Scientific Corporation | $178.66 | 2019-2025 | Watchman Flx |
| Medtronic, INC. | $175.15 | 2021-2024 | Linq II |
| Glaxosmithkline, LLC. | $158.62 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Regeneron Healthcare Solutions, INC. | $147.91 | 2019-2024 | Evkeeza |
| Penumbra, INC. | $123.43 | 2022 | |
| Idorsia Pharmaceuticals US INC | $122.99 | 2022-2023 | Quviviq |
| Sumitomo Pharma America, INC. | $106.04 | 2024-2025 | Gemtesa |
| Lilly USA, LLC | $101.61 | 2020-2025 | Mounjaro, Zepbound |
| Atricure, INC. | $99.40 | 2019 | |
| Sanofi Pasteur INC. | $95.67 | 2022-2024 | |
| Medicomp INC | $95.22 | 2023-2025 | Telepatch Cardiac Monitor |
| Impulse Dynamics (USA) INC. | $91.42 | 2024 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $66.20 | 2023-2024 | Inpefa |
| Heartflow, INC. | $60.28 | 2023-2025 | Ffrct |
| Seqirus USA INC | $49.04 | 2024 | Fluad, Flucelvax |
| Kiniksa Pharmaceuticals, LTD. | $45.05 | 2023 | Arcalyst |
| Lundbeck LLC | $41.27 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.94 | 2024 | Cycloset |
| Shield Therapeutics INC | $39.70 | 2023 | Accrufer |
| Gilead Sciences, INC. | $37.89 | 2019 | |
| Bardy Diagnostics, INC. | $36.35 | 2022 | |
| Currax Pharmaceuticals LLC | $35.67 | 2020 | |
| Exact Sciences Corporation | $33.64 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $30.55 | 2024 | Korlym |
| Kiniksa Pharmaceuticals International, Plc | $23.11 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $22.70 | 2024 | Inspire |
| Amryt Pharma Holdings LTD | $22.53 | 2021 | |
| Daiichi Sankyo INC. | $22.36 | 2024 | Injectafer |
| Bridgebio Pharma, INC. | $20.22 | 2025 | Attruby |
| Althera Pharmaceuticals LLC | $16.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bergman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.